TLR4 and COVID-19: TLR4 modulators, such as Eritoran (NCT02735707), EB05 (NCT04401475), curcumin (NCT04382040), naltrexone (NCT04604704 and NCT04604678), and berberine (NCT04479202), are in clinical trials for COVID‐19.